Benitec Biopharma (BNTC) Depreciation & Amortization (CF) (2019 - 2025)

Benitec Biopharma has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $14000.0 for Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $14000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $54000.0 (down 40.0% YoY), and the FY2025 annual result was $66000.0, down 24.14% from the prior year.
• Depreciation & Amortization (CF) came in at $14000.0 for Q4 2025 at Benitec Biopharma, up from $13000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $67000.0 in Q1 2021 to a low of $6000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $25000.0 (2024), against an average of $30100.0.
• Across the five-year window, Depreciation & Amortization (CF) tumbled 88.46% in 2022 and jumped 250.0% in 2023, its largest moves.
• Benitec Biopharma's Depreciation & Amortization (CF) stood at $55000.0 in 2021, then fell by 25.45% to $41000.0 in 2022, then sank by 58.54% to $17000.0 in 2023, then declined by 17.65% to $14000.0 in 2024, then changed by 0.0% to $14000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $14000.0 (Q4 2025), $13000.0 (Q3 2025), and $14000.0 (Q2 2025), per Business Quant data.